[PDF][PDF] Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
AS Levey, JA Beto, BE Coronado… - American Journal of …, 1998 - academia.edu
AS Levey, JA Beto, BE Coronado, G Eknoyan, RN Foley, BL Kasiske, MJ Klag, LU Mailloux…
American Journal of Kidney Diseases, 1998•academia.eduCVD is the leading cause of death in ESRD. CVD often begins well before the onset of the
end-stage of CRD and is associated with recognizable risk factors. In the general
population, CVD morbidity and mortality have declined substantially over the past three
decades through risk-factor identification and reduction and more effective treatment of CAD.
Indeed, recent clinical trials suggest that further improvements lie ahead. This raises the
important question of whether the strategies for the prevention and treatment of CVD in the …
end-stage of CRD and is associated with recognizable risk factors. In the general
population, CVD morbidity and mortality have declined substantially over the past three
decades through risk-factor identification and reduction and more effective treatment of CAD.
Indeed, recent clinical trials suggest that further improvements lie ahead. This raises the
important question of whether the strategies for the prevention and treatment of CVD in the …
CVD is the leading cause of death in ESRD. CVD often begins well before the onset of the end-stage of CRD and is associated with recognizable risk factors. In the general population, CVD morbidity and mortality have declined substantially over the past three decades through risk-factor identification and reduction and more effective treatment of CAD. Indeed, recent clinical trials suggest that further improvements lie ahead. This raises the important question of whether the strategies for the prevention and treatment of CVD in the general population are applicable to patients with CRD. Answering this question was the principal focus of the NKF Task
academia.edu